Treatment of Steroid Refractory Gastro-intestinal Acute Graft-versus-Host disEase afteR AllogeneiC Hematopoietic Stem celL Transplantation With fEcal Microbiota tranSfer
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Maa-T-013 (Primary)
- Indications Graft-versus-host disease
- Focus Proof of concept; Therapeutic Use
- Acronyms HERACLES
- Sponsors MaaT Pharma
- 12 Oct 2018 According to a MaaT Pharma media release, first patient has been dosed.
- 18 Sep 2018 According to a MaaT Pharma media release, data were presented at the 2018 European Molecular Biology Organization (EMBO) Symposium .The Human Microbiome, being at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.
- 21 Jun 2018 According to a MaaT Pharma media release, the company has received authorization from the French regulatory authorities to start this trial. The company is planning to treat the first patient in the trial in the near future.